Abstract
This article discusses the merits and limits of nonsteroidal antiinflammatory drugs (NSAIDs), including cyclooxygenase (COX)-2 inhibitors, for colorectal cancer prevention. The suppressive effect of NSAIDs on colorectal tumors has been recognized since as early as 1981. The chemopreventive effect of NSAIDs on colorectal tumors in relationship to the inhibition of prostaglandin synthesis is reviewed first. Then, the results of a randomized double-blind clinical test that examined the regressive effect of a COX-2-specific inhibitor on adenoma of familial adenomatous polyposis (FAP) are presented. Other similar trials are also reviewed. The clinical guideline for the use of aspirin, NSAIDs, and COX-2 inhibitors for primary prevention of colorectal cancer that was prepared for the U.S Preventive Services Task Force is introduced. These results suggest that a higher dose of COX-2 inhibitors has a suppressive effect on adenoma of the colon and rectum, although a moderate clinical dose of COX-2 inhibitors does not induce clinically effective suppression of adenoma. In the future, NSAIDs may be tried in combination with other materials to prevent colorectal cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981;41:1954–1957.
Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175–179.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–235.
Myaki M, Konishi M, Kikuchi-Yanoshita R, Enomoto M, Tanaka K, Iwama T, et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res 1994;54:3011–3020.
Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641–649.
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Taketo MM, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803–809.
Iwama T, Akasu T, Utsunomiya J, Muto T. Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int J Clin Oncol 2006;11:133–139.
Moher D, Schulz KF, Atman DG; for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191–1194.
Gann PH. Low-dose aspirin and evidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1182–1184.
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883–890.
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891–899.
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K-M, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873–884.
Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674–1682.
Giardiello FM, Offenhaus JA, Tersmette AC, Hylind LM, Krush AJ, Brensinger JD, et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996;38:578–581.
Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath LD, et al. Primary chemoprevention of familial adenomatous polyposisi with sulindac. N Engl J Med 2002;346:1054–1059.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;242:1946–1952.
Higuchi T, Iwama I, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756–4760.
Solomon SD, McMurray JJV, Pfeffer MS, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–1080.
Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 2007;146:365–375.
Meyskens FL, Gerne EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945–951.
Nie L, Feng W, Diaz R, Gratton MA, Doley KJ, Yamoah EN. Functional consequences of polyamine synthesis inhibition by DFMO: cellular mechanisms for DFMO-mediated ototoxicity. J Biol Chemist 2005;M409856200; www.jbc.org.
Gerne EW, Meiskens FL, Goldschmidt S, Lance P, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids 2007;33:189–195.
Barry ELR, Baron JA, Bhat S, Grau MV, Burke CA, Sandler RS, et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Nat Cancer Inst 2006;98:1494–1500.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iwama, T. NSAIDs and colorectal cancer prevention. J Gastroenterol 44 (Suppl 19), 72–76 (2009). https://doi.org/10.1007/s00535-008-2265-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-008-2265-7